SUMMARY Within four hours of the onset of acute myocardial infarction 57 consecutive patients were randomised blindly to infusion of 150 mg recombinant tissue plasminogen activator (rt-PA) (group 1) over five hours or placebo (group 2) when they were first seen outside hospital or in the accident and emergency department. When they were admitted to the coronary care unit patients in group 1 also had placebo infused and those in group 2 were treated with rt-PA as well as placebo. Treatment with rt-PA started at a mean of 119 minutes (range 38-235) after the onset of pain in group 1 and 187 minutes (range 80-285) after the onset of pain in group 2. In 19 (79%) of 24 in group 1 and 16 of 25 (64%) in group 2 cardiac catheterisation 10-14 days after infarction showed thrombolysis in myocardial infarction grades 2 or 3. There was a mean percentage shortening ofthe infarct related segments (Leighton method) of 16% in group 1 and 10-3% in group 2. For patients with anterior infarction mean percentage shortening was 20 5% in group 1 and 12 2% in group 2. Although there was no significant difference in global ejection fraction as assessed by contrast ventriculography or radionuclide ventriculography the infarct related regional third ejection fraction (a measure of the function of the territory of the affected coronary artery) was significantly improved by early treatment (41% group 1 and 28% group 2). Assessment of infarct size by the QRS scoring method of Palmeri showed QRS score < 3 in 15/25 patients in group 1 and 8/27 in group 2. Nine patients developed 11 episodes of ventricular fibrillation; all patients in whom ventricular fibrillation developed during treatment with rt-PA were successfully resuscitated. There was no clinically significant bleeding. In seven (12%) patients clinical and electrocardiographic criteria suggested reocclusion. Five patients died from cardiac causes.
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Prehospital administration of rt-PA was feasible and significantly reduced the delay before thrombolysis was started. Earlier treatment improved myocardial function in the infarct area and reduced the infarct size.
Recombinant tissue plasminogen activator (rt-PA) patient with evolving acute myocardial infarction used in the acute phase of myocardial infarction is an should further limit myocardial damage and reduce effective thrombolytic agent that improves left infarct size, and thus improve left ventricular funcventricular function after clot lysis." In dogs the tion. To test this hypothesis we performed a double metabolic changes induced by ischaemia increased blind placebo controlled study to compare early and with time from the onset ofexperimental occlusion of late administration of rt-PA to patients in whom a coronary artery.' It follows that earlier lysis of an treatment started within four hours of the onset of occluding thrombus in the coronary artery of a acute myocardial infarction.
Early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction 317 ment of the hospital were considered for entry into the study. All were aged less than 75 years, had had chest pain lasting less than four hours, and had ST segment elevation of 1 mm in at least two standard leads or in two precordial leads of the electrocardiogram. We excluded women of childbearing age; patients with previous cerebrovascular stroke, a history of generalised bleeding diathesis, or recent trauma or operation; or left bundle branch block on the electrocardiogram.
Continuous electrocardiographic monitoring was started, an intravenous cannula was put in place, and diamorphine was given for pain relief. rt-PA (double chain) and placebo for each patient were supplied by Wellcome research laboratories in pre-packed cartons that were used in sequence. When patients became pain free they were randomised blindly to receive rt-PA (group 1) or placebo (group 2). Allocation depended on whether the first colour coded section of the carton contained placebo or active agent. The contents of the vials from this section were dissolved and infused intravenously (fig 1) . Patients then proceeded directly to the coronary care unit where the contents from the second section of the same carton were dissolved and infused, via a line in the contralateral arm, concurrently and at the same rate as the first infusion. Thus patients in group 1 started treatment with rt-PA before admission to the coronary care unit whereas those in group 2 started rt-PA after admission to the coronary care unit. rt-PA (100 or 115 mg) was infused intravenously over 90 minutes and 50 or 35 mg respectively was infused over the next three and a half hours. Intravenous heparin (1000 units/h) was started at the end of the first infusion. Battery powered infusion pumps (Graseby MS 2000 and Graseby MS 16A) were used to deliver rt-PA, placebo, and heparin at the desired rate. area/length method, and regional wall movement in the infarct area was assessed by Leighton's method.5 Segments 2 and 3 were used to assess anterior infarction and 7 and 8 for inferior infarction (figs 2-4). Coronary angiograms were scored by the thrombolysis in myocardial infarction (TIMI) grades (0-3).6 All angiograms and ventriculograms were assessed by experienced investigators who were unaware of the treatment group. Gated blood pool scanning was performed whenever possible during hospital admission or soon after discharge. Global ejection fraction and infarct related regional third ejection fraction (used as a measure of function in the area of infarction) were calculated by an investigator who was unaware of the patient's treatment group. Gated blood pool scanning was performed with an Ohio-Nuclear Sigma 420 Gamma Camera interfaced to an MCS-560 Nuclear Medicine Computer for acquisition and processing data. Global ejection fraction was * I.. There was no difference in mean global ejection fraction between the two groups (table 3). Table 4 shows the percentage shortening ofthe infarct related segments as assessed by the Leighton method. The difference in mean percentage shortening between the two groups is just outside the conventional 95% level of significance (16% v 10-3%, p = 0-06, 95% confidence interval -1 6 to 13). However, for patients with anterior myocardial infarction the mean (SEM) percentage shortening was significantly bet- confidence interval 0-9 to 15-7). There was no significant difference between the two groups when the global ejection fraction was assessed by radionuclide ventriculography (table 5) . However, the infarct related regional third ejection fraction was significantly better for patients in group 1 (41%) than in group 2 (28%) (p < 005, 95%
confidence interval -0O8 to 26-8) (one tailed t test).
The QRS scoring method of Palmeri et al showed that 15/25 patients from group 1 had a QRS score < 3 compared with 8/27 from group 2 (X2 = 4 84, p < 0 05). Of the remaining five patients one had WolffParkinson-White syndrome, one right bundle branch block, and three died before the 48-72 hour electrocardiogram was performed. Nine patients developed 11 episodes of ventricular fibrillation-four patients from group 1 and five from group 2. Of the 11 episodes, seven occurred during treatment with rt-PA, one occurred during placebo, and three occurred after rt-PA infusion (one on day 2 and one on day 5 after infarction and one on day 7 during reinfarction). There were three episodes of ventricular fibrillation during treatment with rt-PA before admission to the coronary care unit and in all three cases resuscitation was successful. Seven of the nine patients with ventricular fibrillation were initially resuscitated and six survived to leave hospital.
In 27 patients there was minor cutaneous bruising at sites of venepuncture or catheterisation or both. One patient developed a bloody ooze from a recent tooth extraction site, one had coffee ground vomit, and two had haematuria (soon after bladder catheterisation in one). No patient required transfusion.
In seven (12%) patients (three in group 1 and four in group 2) clinical and electrocardiographic criteria suggested reocclusion. One of these received a second dose of rt-PA with successful reperfusion.
Five patients died from cardiac causes: three from cardiogenic shock, one from mesenteric embolisation complicating left ventricular mural thrombus -and cardiogenic shock, and one from asystole after ventricular fibrillation. Two of the deaths were in group 1 and three were in group 2.
Discussion
Myocardial damage spreads as a wave front from endocardium to epicardium after occlusion of the infarct related coronary artery. Reducing the delay before lysis of the occluding thrombus is attempted should improve myocardial salvage. Studies of dogs by positron tomography support the hypothesis that earlier removal ofthe intracoronary thrombus results in greater improvement of myocardial metabolism. 7 The potential clinical benefit of early thrombolytic treatment was evident in the results of the Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico which showed that those treated with streptokinase within the first hour ofthe onset of symptoms had the greatest reduction in mortality8 and in the experience with early administration of streptokinase in Jerusalem where patients treated within one and a halfhours after the onset ofpain had a significantly higher ejection fraction than those treated between one and a half and four hours after the onset of pain.9 However, neither of these studies was a controlled comparison of early and late treatment-that is the patient population treated early and those treated later may not have been comparable in terms of other treatments, for example time to In this placebo controlled study we have shown that it is feasible to start thrombolytic treatment with rt-PA outside hospital or in the accident and emergency department. The procedure is safe and significantly reduces the delay in starting thrombolytic treatment. A mean of 68 minutes was saved when rt-PA treatment was started once the diagnosis of myocardial infarction was suspected rather than when the patient was admitted to the coronary care unit. The patient's delay in seeking help caused the greatest delay; transit of the mobile coronary care unit team and the diagnosis of acute infarction and pain relief after arrival of the team with the patient caused less delay.
There were no complications attributable to thrombolytic treatment before admission to hospital. All seven (12%) patients who developed ventricular fibrillation during rt-PA treatment were successfully resuscitated. Ventricular fibrillation was no more common during rt-PA treatment than in an earlier study of acute myocardial infarction without thrombolysis.'°Concern about arrhythmias during thrombolysis should not preclude rt-PA treatment before admission to hospital provided basic monitoring and resuscitation equipment are available. In most patients reperfusion is usually gradual and therefore less likely to be associated with ventricular fibrillation. Only three episodes of ventricular fibrillation occurred after the initial infusion, one on day 2, one on day 5, and one on day 7 during reinfarction.
Although the trend was towards higher reperfusion rates in those treated early (79% v 64%) the difference was not significant. We have already shown that reperfusion rates were improved when rt-PA treatment was started early.' It may be that the difference of 68 minutes to the start of rt-PA infusion between these two groups of patients did not significantly affect the reperfusion rate in group 2. rt-PA infusion was started 187 minutes after infarction in group 2 and we know that the angiographically proven reperfusion rate was 82% in patients treated with 100 mg of rt-PA over 90 minutes who were seen within four hours of the onset of acute myocardial infarction.' The assessment of reperfusion by angiography at 10-14 days is less accurate than immediate angiography because silent reocclusion or spontaneous reperfusion can occur in the interim. Our patients were catheterised at 10-14 days to allow left ventricular function to be assessed by contrast ventriculography. Early treatment did not significantly improve mean global left ventricular ejection fraction (tables 3 and 5). However, the infarct related regional third ejection fraction was significantly better in group 1 than in group 2 (41% v 28%, p < 0-05) (table 5) and the improvement in infarct related regional wall movement was almost statistically significant (16-0 (2-7)% v 10 3 (2-56)%) (p = 0-06) (table 4).
In group 1 there were 13 patients with anterior infarction and 14 with inferior infarction and in group 2, 18 patients with anterior infarction, 11 with inferior infarction, and one with lateral infarction. In patients with anterior infarction the regional wall movement was significantly improved by early treatment (20-5 (2.99)% v 12-2 (2 23)% (p = 0-01)).
Global ejection fraction is a crude estimate of left ventricular function in patients with infarction because it may be reduced by previous infarction, because hyperkinesis in a non-infarct zone may compensate for hypokinesis in the infarct area, and because return towards normal of this compensatory hyperkinesis may mask thrombolytically induced improvement in the infarct area. This may account for the improvement in left ventricular function in the infarct area without apparent significant improvement in the overall left ventricular ejection fraction as shown by both radionuclide and contrast ventriculography. Left ventricular ejection fraction and regional wall movement were no better in patients with inferior infarction who were treated earlier; nevertheless we believe that thrombolysis should be started as early as possible in patients with inferior infarction because a patent circumflex or right coronary artery may be an important source of collaterals to the anterior surface of the myocardium in patients with previous or future anterior infarction.
The improvement in infarct size with earlier treatment and as assessed by QRS scoring accorded with previous studies of early thrombolytic treatment.9 Although QRS scoring is a crude estimate of infarct size it correlates well with left ventricular function4 and is an easily applicable measure of myocardial salvage.
We have shown that thrombolytic treatment can be started safely by medical staff on a mobile coronary care unit; but this is not the only approach to thrombolytic treatment before admission to hospital.
In areas where there are no mobile coronary care units with medical staff thrombolysis could be given by general practitioners or suitably trained paramedical personnel with adequate medical supervision probably by telephone. Infusion of rt-PA before hospital admission appreciably reduced the delay in starting thrombolysis. Earlier treatment improved myocardial function in the infarct related area and reduced infarct size. Our results confirm the advantages of reducing the delay before thrombolytic treatment. 320 group.bmj.com on June 15, 2017 -Published by http://heart.bmj.com/ Downloaded from
